Hutchison China MediTech (Chi-Med)
21st Floor, Hutchison House
10 Harcourt Road
About Hutchison China MediTech (Chi-Med)Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.
CEO: Christian Hogg
CFO: Johnny Cheng
CSO: Weiguo Su
191 articles about Hutchison China MediTech (Chi-Med)
HUTCHMED Limited, formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement released on Wednesday, April 28, 2021, the Registrar of Companies in the Cayman Islands has issued a replacement certificate of incorporation on Thursday, April 29, 2021 in the name of HUTCHMED Limited so the new name of the Company is now effective from April 29, 2021.
HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
Hutchison China MediTech Limited has initiated a registration-intent Phase II clinical trial of HMPL-689, its highly selective and potent PI3Kδ inhibitor, in China in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma, two subtypes non-Hodgkin’s lymphoma.
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Hutchison China MediTech Limited has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients with advanced solid tumors in the U.S. and Europe.
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT
Hutchison China MediTech Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage biopharmaceutical company, today reports its audited financial results for the year ended December 31, 2020 and provides updates on key clinical and commercial developments.
Hutchison China MediTech Limited will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time / 8:00 pm Hong Kong Time / 7:00 am Eastern Standard Time.
Hutchison China MediTech Limited announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer, taking place on January 28-31, 2021, virtually.
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Hutchison China MediTech Limited and Inmagene Biopharmaceuticals announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
– Sulanda ® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio – – ~400-strong oncology commercial team in place to bring Sulanda ® to patients in China – HONG KONG and FLORHAM PARK, N.J., Dec. 30,
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio – – First NDA submission by Ch
Hutchison China MediTech Limited announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8 a.m. EST.
Hutchison China MediTech Limited announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be presented as a poster at the upcoming 62nd American Society of Hematology Annual Meeting and Exposition, taking place on December 5-8, 2020 virtually.
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”)
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Hutchison China MediTech Limited announces that its New Drug Application for surufatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors has been accepted for review by the China National Medical Products Administration.
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Hutchison China MediTech Limited has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metastatic colorectal cancer in the U.S., Europe and Japan.
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
Hutchison China MediTech Limited has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors, in patients with advanced intrahepatic cholangiocarcinoma, which is a type of liver cancer.
Hutchison China MediTech Limited announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology Virtual Congress 2020, taking place on September 17-21, 2020.
Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
Hutchison China MediTech Limited announces that it received scientific advice from the European Medicines Agency's Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET 3 Exon 14 skipping mutation NSCLC 4 , and surufatinib in pancreatic NET 5 – – Expansion of commercial activities in oncology – Chi-Med to be responsible for medical detailing and marketing for Elunate ® throughout Mainlan